Treatment of neuromyelitis optica: An evidence based review;Tratamento da neuromielite óptica: Uma revisão baseada em evidências

Arquivos de Neuro-Psiquiatria

Volumn 70, Issue 1, 2012, Pages 59-66

  Sato, Douglas ^a,b   Callegaro, Dagoberto ^b   Lana Peixoto, Marco Aurélio ^c   Fujihara, Kazuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Aquaporin 4; Azathioprine; Cyclophosphamide; Interferon beta; Mitoxantrone; Monoclonal antibodies; Mycophenolic acid; Neuromyelitis optica; Plasmapheresis; Steroids; Therapy

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; GLATIRAMER; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ABDOMINAL PAIN; ALLERGY; ALOPECIA; ANOREXIA; ANXIETY; ARTICLE; ASEPTIC NECROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CLOTTING DISORDER; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONSTIPATION; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FERTILITY; FEVER; FLUID RETENTION; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GUILLAIN BARRE SYNDROME; HAIR LOSS; HEADACHE; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLAMMATION; INTRAOCULAR PRESSURE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; LUNG EDEMA; MAINTENANCE THERAPY; MALAISE; MONOTHERAPY; MOOD CHANGE; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NAUSEA; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PLASMAPHERESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RELAPSE; RHEUMATIC DISEASE; SIDE EFFECT; SKIN BRUISING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; WEGENER GRANULOMATOSIS;

EID: 84855518068     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2012000100012     Document Type: Article

References (55)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
3. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-968.
4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
5. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-132.
6. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-1220.
7. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-974.
8. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-1243.
9. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-3080.
10. United States Department of Health and Human Services. Agency for Health Care Policy and Research (AHCPR). Acute pain management: operative or medical procedures and trauma. Clinical practice guideline No 1, AHCPR publication No 92-0023. Rockville, MD: AHCPR; 1993.
11. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006;129:174-181.
12. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001;117:1-8.
13. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435-442.
14. Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010;248:1777-1785.
15. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999;131:453-462.
16. Balogun RA, Kaplan A, Ward DM, et al. Clinical applications of therapeutic apheresis. J Clin Apher 2010;25:250-264.
17. Yoshida H, Ando A, Sho K, et al. Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis. J Ocul Pharmacol 2010;26:381-385.
18. Keller AJ, Urbaniak SJ. Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol 1978;38:531-540.
19. Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989;29:124-127.
20. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146.
21. Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009;13:505-508.
22. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update. Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300.
23. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886.
24. Munemoto M, Otaki Y, Kasama S, et al. Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis. J Clin Neurosci 2011;18:478-480.
25. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.
26. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177.
27. Carroll W, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010;12:244-255.
28. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010;11:177-188.
29. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010;67:1131-1136.
30. Tanaka Y, Kimura K, Kawachi I, Inuzuka T. No relapse of neuromyelitis optica during drug-induced B-lymphopenia with hypogammaglobulinemia. Neurology 2010;75:1745-1747.
31. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.
32. Imamura H, Tanaka M, Kitagawa N, et al. Trial of rituximab in three patients with neuromyelitis optica. Rinsho Shinkeigaku 2009;49:457-462.
33. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007;28:209-211.
34. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 2011;18:997-998.
35. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.
36. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011:Epub May 26.
37. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310-1315.
38. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011:Epub July 11.
39. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332-1338.
40. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-963.
41. Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology 2006;45:913-915.
42. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-1133.
43. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991;337:441-446.
44. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-918.
45. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 2008;35:172-174.
46. Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008;4:381-386.
47. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252:57-61.
48. Shimizu Y, Fujihara K, Kubo S, et al. Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis. Tohoku J Exp Med 2011;223:211-214.
49. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010;17:672-676.
50. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-259.
51. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-1017.
52. Mayo Clinic. An open label study of the effects of eculizumab in neuromyelitis optica (http://clinicaltrials.gov/ct2/show/NCT00904826).
53. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-1243.
54. Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004;31:265-267.
55. Bergamaschi R, Uggetti C, Tonietti S, Egitto MG, Cosi V. A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 2003;250:359-361.